Pipracil Related Published Studies
Well-designed clinical trials related to Pipracil (Piperacillin)
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. [2011.05]
Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). [2011.02]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. [2010.08]
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. [2010.04]
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. [2010.04]
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. [2009.10]
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. [2009.04]
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? [2009.03]
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. [2008.05]
Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. [2007]
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. [2006.11]
A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. [2006.08.15]
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. [2006.08]
Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. [2006.08]
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. [2006.06]
[Controlled, open, parallel-group study of the clinical and microbiological efficacy of piperacillin-tazobactam versus metronidazole + gentamicin in urgent colorectal surgery] [2006.06]
[Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections] [2006.06]
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. [2006.04]
Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. [2006.04]
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. [2006.03]
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. [2006.02]
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. [2005.11.12]
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. [2005.11]
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. [2005.08]
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. [2005.08]
Piperacillin-sulbactam versus piperacillin-tazobactam: a multicentre, randomised, single-blind, controlled clinical trial. [2005.07]
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. [2005.06]
An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. [2005.03]
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. [2005.01]
Well-designed clinical trials possibly related to Pipracil (Piperacillin)
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
A protocol for a multicentre randomised controlled trial of continuous
beta-lactam infusion compared with intermittent beta-lactam dosing in critically
ill patients with severe sepsis: the BLING II study. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
[Perioperative antibiotic prophylaxis in radical retropubic prostatectomy: a randomised pilot study of perioperative and postoperative administration]. [2011.01]
Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. [2009.10]
[Current status of the management of pediatric infective endocarditis: a national survey] [2009.08]
A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. [2006.06]
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. [2006.02]
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. [2005.07]
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. [2005.07]
Management of diabetic foot in a Jordanian hospital. [2005.05]
Other research related to Pipracil (Piperacillin)
Prospective randomized comparison study of piperacillin/tazobactam and meropenem
for healthcare-associated pneumonia in Japan. [2013]
Randomized comparison of piperacillin-tazobactam plus amikacin versus
cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in
children with lymphoma and solid tumors. [2013]
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed
by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections:
results of the RELIEF study. [2013]
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam
in healthy adult subjects. [2012]
Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. [2011.12.15]
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. [2011.11]
The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. [2011.08]
Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa. [2011.07]
Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia. [2011.06.14]
Drug fever due to piperacillin/tazobactam loaded into bone cement. [2011.02]
Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. [2011.02]
Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient. [2011]
Microbiological equivalence of bacteriostatic and bactericidal activities of the
sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz)
and original piperacillin/tazobactam (Tazocin). [2011]
Piperacillin/tazobactam versus cefozopran for the empirical treatment of
pediatric cancer patients with febrile neutropenia. [2011]
[Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward]. [2010.12]
Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens. [2010.11]
Delayed-type hypersensitivity reaction to piperacillin/tazobactam in a patient with an infected total knee replacement. [2010.11]
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. [2010.10]
Electrolytes imbalance: a rare side effect of piperacillin/ tazobactam therapy. [2010.06]
The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. [2010.06]
Daily serum piperacillin monitoring is advisable in critically ill patients. [2010.05]
Protective Effect of Citropin 1.1 and Tazobactam-Piperacillin Against Oxidative Damage and Lethality in Mice Models of Gram-Negative Sepsis. [2010.04.20]
Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital. [2010.04.15]
Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis. [2010.04]
Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis. [2010.04]
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. [2010.03.18]
Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. [2010]
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk
for aspiration: comparison with imipenem/cilastatin. [2010]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as
empirical treatment of febrile neutropenia in cancer patients: results of an open
randomized trial at a university hospital. [2010]
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot
infections: a prospective, randomized clinical trial in a university hospital. [2010]
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile
neutropenia. [2010]
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. [2009.10.14]
IMIPENEM CILASTATIN VERSUS PIPERACILLIN TAZOBACTAM AS MONOTHERAPY IN FEBRILE NEUTROPENIA. [2009.09.07]
A multicenter study on optimizing piperacillin-tazobactam use: lessons on why interventions fail. [2009.08]
Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration. [2009.08]
Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. [2009.06]
Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. [2009.05]
Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. [2009.04]
[Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy] [2009.01.06]
The use of piperacillin-tazobactam in neonatal and paediatric patients. [2009.01]
A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia. [2009]
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. [2008.12]
Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. [2008.12]
Inhibition of flucloxacillin tubular renal secretion by piperacillin. [2008.11]
Piperacillin-tazobactam penetration into human pancreatic juice. [2008.11]
Serological studies of piperacillin antibodies. [2008.11]
False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem? [2008.11]
A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of fever in patients with acute leukemia. [2008.08]
Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. [2008.08]
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. [2008.07.25]
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. [2008.07]
[The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients] [2008.07]
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. [2008.06]
Pharmacoeconomics of Ciprofloxacin plus Metronidazole vs. Piperacillin-Tazobactam for Complicated Intra-Abdominal Infections. [2008.06]
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. [2008.03.15]
Optimized LC-MS/MS quantification method for the detection of piperacillin and application to the development of charged liposaccharides as oral penetration enhancers. [2008.03.03]
Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. [2008.02]
Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. [2008.01]
Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis. [2008.01]
|